Mouse IgA modulates human gut microbiota with inflammatory bowel disease patients
Journal of Gastroenterology · 2024-09 · 59 (9) · 812-824
DOI: 10.1007/s00535-024-02121-y ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gastroenterology, online erschienen am 14.06.2024. Verfasst von Keishu Takahashi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Quantitative Biosciences, The University of Tokyo, Bunkyo-ku, Tokyo, Japan, Laboratory of Immunology and Infection Control. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Dysbiosis, Inflammatory Bowel Diseases, Immunoglobulin A. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: JST SPRING, AMED, The University of Tokyo.
Abstract (Originalsprache)
Background
The imbalance of commensal bacteria is called dysbiosis in intestinal microflora. Secreted IgA in the intestinal lumen plays an important role in the regulation of microbiota. Although dysbiosis of gut bacteria is reported in IBD patients, it remains unclear what makes dysbiosis of their microflora. The intervention method for remedy of dysbiosis in IBD patients is not well established. In this study, we focused on the quality of human endogenous IgA and investigated whether mouse monoclonal IgA which binds to selectively colitogenic bacteria can modulate human gut microbiota with IBD patients.
Methods
IgA-bound and -unbound bacteria were sorted by MACS and cell sorter. Sorted bacteria were analyzed by 16S rRNA sequencing to investigate what kinds of bacteria endogenous IgA or mouse IgA recognized in human gut microbiota. To evaluate the effect of mouse IgA, gnotobiotic mice with IBD patient microbiota were orally administrated with mouse IgA and analyzed gut microbiota.
Results
We show that human endogenous IgA has abnormal binding activity to gut bacteria in IBD patients. Mouse IgA can bind to human microbiota and bind to selectively colitogenic bacteria. The rW27, especially, has a growth inhibitory activity to human colitogenic bacteria . Furthermore, oral administration of mouse IgA reduced an inflammation biomarker, fecal lipocalin 2, in mice colonized with IBD patient-derived microbiota, and improved dysbiosis of IBD patient sample.
Conclusion
Oral treatment of mouse IgA can treat gut dysbiosis in IBD patients by modulating gut microbiota.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Quantitative Biosciences, The University of Tokyo, Bunkyo-ku, Tokyo, Japan, Laboratory of Immunology and Infection Control.
- Graduate School of Frontier Science, The University of Tokyo, Kashiwa, Chiba, Japan.
- Department of Gastroenterology, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Ishikawa, Japan.
- Department of Medicine, Shiga University of Medical Science, Otsu, Shiga, Japan.
- Department of Gastroenterology, Nagahama City Hospital, Nagahama, Shiga, Japan.
- Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.
Förderung
- JST SPRING
- AMED
- The University of Tokyo
Zitieren
APA
Takahashi, K., Morita, N., Tamano, R., Gao, P., Iida, N., Andoh, A., Imaeda, H., Kurokawa, K., Tsuboi, M., Hayakawa, Y., Fujishiro, M., & Shinkura, R. (2024). Mouse IgA modulates human gut microbiota with inflammatory bowel disease patients. Journal of Gastroenterology, 59(9), 812-824. https://doi.org/10.1007/s00535-024-02121-y
Vancouver
Takahashi K, Morita N, Tamano R, Gao P, Iida N, Andoh A, et al. Mouse IgA modulates human gut microbiota with inflammatory bowel disease patients. Journal of Gastroenterology. 2024;59(9):812-824. doi:10.1007/s00535-024-02121-y
BibTeX
@article{Takahashi2024,
author = {Takahashi, Keishu and Morita, Naoki and Tamano, Ryutaro and Gao, Peng and Iida, Noriho and Andoh, Akira and Imaeda, Hirotsugu and Kurokawa, Ken and Tsuboi, Mayo and Hayakawa, Yoku and Fujishiro, Mitsuhiro and Shinkura, Reiko},
title = {Mouse IgA modulates human gut microbiota with inflammatory bowel disease patients},
journal = {Journal of Gastroenterology},
year = {2024},
volume = {59},
number = {9},
pages = {812--824},
doi = {10.1007/s00535-024-02121-y}
}
EUVIMED